Tumor immunomodulator and application thereof

An immunomodulator and immunomodulatory technology, applied in the field of tumor treatment, can solve problems such as the inability to exert the body's immunity and the weak immunity of the patient.

Pending Publication Date: 2020-03-03
SHANGHAI YUANXI MEDICINE CORP
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, the patient's own immunity will be in a very weak state for a long time after the operation, and the normal body immunity cannot be exerted. How to improve the body's immunity and stabilize the body's immune system after the operation is the key to controlling the recurrence of tumors after the operation. a problem of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor immunomodulator and application thereof
  • Tumor immunomodulator and application thereof
  • Tumor immunomodulator and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] Example 1 Effect of BS on the immune system of mice

[0104] Twenty-four normal male KM mice with a body weight of 18-22 g were randomly divided into 4 groups, namely BS low-dose, medium-dose and high-dose groups and a control group, with 6 animals in each group, and were inoculated with mouse liver cancer H22 cells (2×10 6 each / only) after the 2nd day of administration. Dosage: blank control group (5‰CMC-Na, i.g., q.d.); BS low-dose group (90mg·kg -1 , i.g., q.d.); BS medium dose group (180mg·kg -1 , i.g., q.d.); BS high-dose group (360mg·kg -1 , i.g., q.d.). The state of the mice was observed every day for 8 consecutive days.

[0105] Hereinafter, BSL, BSM, and BSH represent BS low, middle, and high dose groups.

[0106] 1.1 Effect of BS on body weight of mice

[0107] Such as figure 1 as shown, figure 1The changes in body weight of mice in each group during the administration were summarized. Compared with the control group, there was no significant differ...

Embodiment 2

[0138] Example 2 Immunological observation of BS in postoperative recurrence model

[0139] 2.1 Effect of BS on body weight of tumor-bearing H22 mice

[0140] In the mouse H22 liver cancer xenograft tumor resection model established in Balb / c mice, the body weight change monitoring of the mice during the administration showed as follows: Figure 6 Shown, each administration group compares with control group, and there is no significant difference in body weight, all increases gradually, and the body weight of low-dose administration group and high-dose administration group declines slightly in the 8th day, has no statistical difference. Control group, the low (90mg / kg), middle (180mg / kg), high (360mg / kg) dose administration groups of BS increased to 1.12 ± 0.06, 1.12 ± 0.05, 1.15 ± 0.05 of the initial body weight respectively on the eighth day 0.15, 1.10±0.07 times, no significant difference was found, indicating that BS has no obvious toxicity to mice.

[0141] 2.2 The effe...

Embodiment 3

[0160] Example 3 BS combined with cisplatin (CDDP) postoperatively induces immunomodulatory effect

[0161] BS administration group (180mg / kg): Weigh 180mg of BS original drug, dissolve it in 5mL 5‰ CMC-Na solution to make a suspension, and the administration dose is 5mL / kg;

[0162] Cisplatin administration group (2 mg / kg): Weigh 2 mg of cisplatin, dissolve it in 5 mL of normal saline to make a solution, and the administration dose is 5 mL / kg.

[0163] Combined administration group: BS (180 mg / kg) and cisplatin (2 mg / kg) were administered at the same time, and the dosage was 5 mL / kg.

[0164] Balb / c mice were selected to establish mouse Lewis lung cancer xenograft tumor resection models, and were sacrificed on the second day of surgery after continuous administration for eight days. The mice were dissected, the tumors were completely removed, and the volume was weighed and analyzed accordingly. When it is used in vivo, since the metabolism of the drug in the body has a great...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of tumor treatment, and discloses a tumor immunomodulator and application thereof. The immunomodulator at least comprises a benzoisoselenazole derivative,preferably comprises a benzoisoselenazole derivative and a platinum anticancer drug. The molar ratio of the benzoisoselenazole derivative to the platinum anticancer drug is (1-99): (1-99). The immunomodulator can be used for tumor therapy, such as early tumor immunomodulation and postoperative tumor recurrence immunomodulation. The coordination effect of apoptosis induction and immunoregulation ofBS makes it possible for BS to be used as a long-term postoperative tumor recurrence control regulator that benefits patients. Furthermore, the combined application of BS and cisplatin will amplify the coordination effect, thus benefiting more clinical patients.

Description

technical field [0001] The invention belongs to the technical field of tumor treatment, and in particular relates to a tumor immunomodulator and its application. Background technique [0002] The phenomenon that tumor cells survive and proliferate in vivo by evading the recognition and attack of the body's immune system through various mechanisms is called tumor immune escape. The body's immune system has the function of immune surveillance. When malignant cells appear in the body, the immune system can recognize and specifically eliminate these "non-self" cells through the immune mechanism to resist the occurrence and development of tumors. However, in some cases, malignant cells can escape the body's immune surveillance through various mechanisms, proliferate rapidly in the body, and form tumors. That is to say: on the one hand, the body can resist the occurrence of tumors through natural and acquired immunity; on the other hand, tumor cells can escape the recognition and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/41A61K33/243A61K31/555A61P35/00A61P35/02A61P37/04
CPCA61K31/41A61K33/24A61K31/555A61P35/00A61P35/02A61P37/04A61K2300/00
Inventor 尹汉维曾慧慧
Owner SHANGHAI YUANXI MEDICINE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap